source
- Novo falls behind Eli Lilly in market race as investors react to Q3 resultsA year ago the competition between Eli Lilly and Novo was described as the fiercest in the industry. Recent commentary suggests the rivalry has become increasingly one‑sided, with Novo struggling t…
- China rises on biotech risk list as US draft rules threaten Chinese biopharma investmentsA recent Signal Survey shows China moving up the biotech industry’s concern list even before the Treasury Department issued draft rules that could curb U.S. investment in Chinese biopharma. The pr…